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Background
Among patients with cardiac arrest, preliminary data
have shown improved return of spontaneous circulation
and survival to hospital discharge with the vasopressin-
steroids-epinephrine (VSE) combination.
Methods
Objective: To determine whether combined vasopressin-
epinephrine during cardiopulmonary resuscitation (CPR)
and corticosteroid supplementation during and after
CPR improve survival to hospital discharge with a Cere-
bral Performance Category (CPC) score of 1 or 2 in
vasopressor-requiring, in-hospital cardiac arrest.
Design: Randomized, double-blind, placebo-controlled,
parallel-group trial performed from 1 September 2008 to
1 October 2010.
Setting: Three Greek tertiary care centers.
Subjects: Consecutive in-hospital cardiac arrest patients
requiring epinephrine and aged more than 18 years
(n = 268).
Intervention: Patients received either vasopressin (20 IU/
CPR cycle) plus epinephrine (1 mg/CPR cycle; cycle
duration approximately 3 minutes; VSE group, n = 130)
or saline placebo plus epinephrine (1 mg/CPR cycle;* Correspondence: huangdt@upmc.edu
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2014cycle duration approximately 3 minutes; control group,
n = 138) for the first 5 CPR cycles after randomization,
followed by additional epinephrine if needed. During the
first CPR cycle after randomization, patients in the VSE
group received methylprednisolone (40 mg) and patients
in the control group received saline placebo. Shock after
resuscitation was treated with stress-dose hydrocortisone
(300 mg daily for 7 days maximum and gradual taper;
VSE group, n = 76) or saline placebo (control group,
n = 73).
Outcomes: Return of spontaneous circulation (ROSC)
for 20 minutes or longer and survival to hospital
discharge with a CPC score of 1 or 2.
Results
Follow-up was completed in all resuscitated patients.
Patients in the VSE group versus patients in the control
group had higher probability for ROSC for 20 minutes
or longer (109/130 (83.9%) versus 91/138 (65.9%); odds
ratio (OR), 2.98; 95% confidence interval (CI), 1.39 to
6.40; P = 0.005) and survival to hospital discharge with
CPC score of 1 or 2 (18/130 (13.9%) versus 7/138 (5.1%);
OR, 3.28; 95% CI, 1.17 to 9.20; P = 0.02). In the subset of
subjects with post-resuscitation shock, subjects in the
VSE group versus patients in the control group had
higher probability for survival to hospital discharge with
CPC scores of 1 or 2 (16/76 (21.1%) versus 6/73 (8.2%);
OR, 3.74; 95% CI, 1.20 to 11.62; P = 0.02), improved
hemodynamics and central venous oxygen saturation,
and less organ dysfunction. Adverse event rates were
similar in the two groups.
Conclusions
Among patients with cardiac arrest requiring vasopressors,
combined vasopressin-epinephrine and methylprednisolone
during CPR and stress-dose hydrocortisone in postresus-
citation shock resulted in improved survival to hospital
discharge with favorable neurological status compared with
epinephrine.tral Ltd. This is an Open Access article distributed under the terms of the
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In-hospital cardiac arrest is associated with significant
morbidity and mortality. Among in-hospital post-cardiac
arrest patients, survival to hospital discharge is approxi-
mately 20%. Among these survivors, the prevalence of
severe disability or vegetative state ranges from 25% to
50% [1].
During resuscitation from cardiac arrest, coronary
perfusion pressure is driven by the difference between
aortic diastolic pressure and right atrial pressure [2,3].
Vasopressor drugs act primarily by increasing aortic
diastolic pressure and systemic vascular resistance, thus
increasing coronary perfusion pressure. For many years
epinephrine has been the standard vasopressor recom-
mended in Advanced Cardiac Life Support algorithms.
Epinephrine acts on both α- and β-receptors, increasing
peripheral vasoconstriction and cardiac stimulation. The
α-adrenergic effects are believed to be primarily respon-
sible for increasing myocardial and cerebral blood flow
and facilitating return of spontaneous circulation (ROSC).
The β-effects of epinephrine on the heart are not benefi-
cial during or after cardiac arrest, and may worsen
post-resuscitation myocardial dysfunction and increase
myocardial oxygen consumption [4,5].
Vasopressin, an endogenous peptide synthesized in the
hypothalamus, has been proposed as an adjunct to epi-
nephrine in management of cardiac arrest [6]. Vasopres-
sin causes vasoconstriction of skin, skeletal muscle, and
splanchnic circulation, thus increasing peripheral arterial
resistance [7]. These effects are mediated via V1 recep-
tors, but unlike epinephrine, vasopressin has no direct
effects on the myocardium [8]. Vasopressin dilates cere-
bral blood vessels to a greater extent than epinephrine, it
has a longer half-life, and its effect is not diminished by
acidosis, common in prolonged cardiac arrest [8]. Fur-
ther support for possible benefits of vasopressin during
cardiac arrest comes from the observation that vaso-
pressin levels in post-cardiac arrest patients are higher
in survivors compared to non-survivors [9,10]. The role
of steroids in stress states has been well studied and may
be beneficial in cardiac arrest patients for several
reasons. Steroids attenuate the systemic inflammatory
response syndrome (SIRS) and improve cerebral perfu-
sion. Cardiac arrest is a high stress state that is associ-
ated with SIRS-like response [6,11], decreased perfusion
of the adrenal glands, and lower cortisol levels during
and after cardiopulmonary resuscitation (CPR) [6]. The
release of adrenal hormone per se is impaired in post-
cardiac arrest patients, thus leading to inadequate
response to the physiological insult [11-13]. The benefi-
cial role of adrenal activation during cardiac arrest is
supported by the high adrenocorticotropic hormone
levels in successfully resuscitated cardiac arrest patients
[14] and low serum cortisol levels in patients with earlypost-resuscitation mortality [11]. In addition, steroids
potentiate the effects of the vasoconstrictors by facilita-
ting intracellular signaling by vasoconstrictor receptors
[15,16].
Based on the above rationale, the authors first demons-
trated beneficial effects of the combination of epinephrine,
vasopressin and corticosteroids for in-hospital cardiac
arrest in a small, single-center pilot randomized clinical trial
(n = 100) [17]. The authors found that the intervention
group when compared to the control group had more
frequent ROSC (81% versus 52%), and improved survival to
hospital discharge (19% versus 4%). This study, however,
lacked neurologic outcome data, and had a small sample
size.
The authors therefore performed a multicenter random-
ized control trial in three tertiary centers in Greece, with a
larger sample size (300 subjects), using survival to hospital
discharge with good neurologic function (Cerebral Per-
formance Category (CPC) score 1 or 2) as the primary
outcome. A single randomization point assigned subjects to
a treatment strategy of vasopressin, epinephrine, and corti-
costeroids (VSE group) or a treatment strategy of only
epinephrine (Epi group). In this study, the VSE group
showed a higher rate of ROSC, and increased survival to
hospital discharge with preserved neurological function
compared to the Epi group. The authors concluded that
adding vasopressin and steroids to epinephrine during the
resuscitation phase of in-hospital cardiac arrest and con-
tinuing use of steroids in post-resuscitation shock improves
survival and neurological outcomes.
In a disease state with very poor survival rate, this is the
first randomized controlled trial showing positive neuro-
logical outcomes with pharmacotherapy. The study authors
used multiple methods to confirm internal validity. They
deployed chromatography to ascertain drug stability, used
appropriate double blinding (masked allocation) through-
out the course of the study, and employed sound monitor-
ing protocols with high follow-up rates. The authors
acknowledged crossover contamination in both arms.
A major limitation of this study is the use of multiple
interventions at the same time in both arms, making it
difficult to discern which one of these interventions
causes benefit. Most of the difference in survival be-
tween groups was already apparent at ROSC, raising
some question as to whether the subsequent steroids in
the post-cardiac arrest care were necessary. Nonetheless,
the combination VSE strategy showed improved neuro-
logical outcomes in a condition with extremely poor
survival. It is possible that each of these drugs alone is
insufficient to affect outcome, but the combination is
synergistic. Alternatively, the VSE regimen resulted in
less total epinephrine use, and the beneficial effect of
VSE may be related to reduced harm from high doses of
epinephrine. Further trials with multi-arm intervention
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vasopressin and steroids may delineate the precise role
of each individual agent.
The authors demonstrated improved outcomes using a
combination of epinephrine, vasopressin and high dose
steroids. The benefits of this triple-agent combination
along with its ease of implementation and low cost offset
the risks in a disease with such high mortality, making
these treatment options attractive for immediate use in
clinical practice.
Recommendation
Given the paucity of proven interventions for, and the
high mortality in, hospital cardiac arrest patients, it is
reasonable to consider a combination of vasopressin,
steroids and epinephrine during resuscitation and during
the post-resuscitation shock phase.
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